2021
Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma.
Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. Journal Of Clinical Oncology 2021, 39: 1119-1128. PMID: 33411586, DOI: 10.1200/jco.20.01849.Peer-Reviewed Original ResearchConceptsTransplant-ineligible patientsIncremental cost-effectiveness ratioFirst-line settingHealthcare costsClinical outcomesMultiple myelomaProgression-free survivalOverall survival dataUS payer perspectiveDirect healthcare costsCost-effectiveness ratioRandomized trialsDisease progressionTreatment strategiesParametric survival modelingPayer perspectiveSubsequent linesLater linesPatientsCostly treatmentIncremental costQALYSurvival dataLenalidomideMyeloma
2020
Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older Patients
Di M, Huntington SF, Olszewski AJ. Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older Patients. The Oncologist 2020, 26: 120-132. PMID: 33230948, PMCID: PMC7873335, DOI: 10.1002/onco.13610.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaChimeric antigen receptor T-cell therapyB-cell lymphomaChemotherapy-free approachProphylactic growth factorsOlder patientsStem cell transplantationT-cell therapyClinical trialsGeriatric vulnerabilitiesRefractory settingGeriatric assessmentCell transplantationPalliative careStandard first-line treatmentGrowth factorEarly palliative careFit older patientsTolerance of treatmentUnfavorable biologic featuresUnnecessary dose reductionsFirst-line settingFirst-line treatmentFavorable toxicity profileReal-World IgG Testing Frequency and Characteristics Associated with Hypogammaglobulinemia after Anti-CD20 Exposure in Patients with Chronic Lymphocytic Leukemia (CLL)
Hooley I, Maignan K, Jacob A, Medina A, Benderoff L, Chen R, Huntington S. Real-World IgG Testing Frequency and Characteristics Associated with Hypogammaglobulinemia after Anti-CD20 Exposure in Patients with Chronic Lymphocytic Leukemia (CLL). Blood 2020, 136: 43-44. DOI: 10.1182/blood-2020-137094.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaCurrent equity holderIgG testCD20 mAbsBaseline characteristicsIgG levelsSevere hypogammaglobulinemiaHigher likelihoodCD20 monoclonal antibody therapyLogistic regressionUnknown statusAnti-CD20 therapyFirst-line settingClinical baseline characteristicsReal-world cohortSimilar baseline characteristicsMonoclonal antibody therapyPotential adverse eventsHypothesis-generating studyDe-identified databaseCurrent employmentCD20 administrationCD20 therapyConcurrent chemotherapyIgG testing
2019
Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States
Huntington S, Soulos P, Barr P, Jacobs R, Lansigan F, Odejide O, Schwartzberg L, Davidoff A, Gross C. Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States. Blood 2019, 134: 797. DOI: 10.1182/blood-2019-122054.Peer-Reviewed Original ResearchFirst-line settingChronic lymphocytic leukemiaFlatiron Health databaseECOG performance statusFirst-line treatmentEarly discontinuationMultivariable logistic regressionPerformance statusIbrutinib discontinuationSpeakers bureauClinical trialsCLL diagnosisCLL therapyLymphocytic leukemiaHealth databasesLogistic regressionBruton tyrosine kinase inhibitorsFirst-line ibrutinibUse of ibrutinibWorse performance statusPoor performance statusRetrospective cohort studyCommunity oncology settingClinical decision support toolCommunity oncology practices
2018
Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma
Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA. Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. Journal Of Clinical Oncology 2018, 36: jco.18.00122. PMID: 30285558, PMCID: PMC6241679, DOI: 10.1200/jco.18.00122.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioFirst-line settingFirst-line therapyBrentuximab vedotinHodgkin's lymphomaHealth care costsStage IIICare costsDirect health care costsLifetime health care costsOpen-label trialCohort of patientsRisk of progressionUS payer perspectiveMarkov decision-analytic modelCost-effectiveness ratioDecision analytic modelFavourable cost effectivenessCost-effectiveness analysisStandard ABVDClinical outcomesPayer perspectiveParametric survival distributionsIndication-specific pricingCost effectiveness